Gene Name |
|
Fold Change |
Growth arrest and DNA-damage-inducible, beta (GADD45B) |
Up-regulated by exenatide & palmitate vs. palmitate in non-diabetic human islets |
2.7 ± 0.001 * † |
|
|
|
|
Down-regulated by pioglitazone & palmitate vs. palmitate in diabetic human islets |
-1.8 ± 0.002 * † |
|
|
|
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) |
Up-regulated by exenatide & palmitate vs. palmitate in non-diabetic human islets |
8.4 ± 0.001 * † |
|
Up-regulated by pioglitazone & palmitate vs. palmitate in non-diabetic human islets |
2.0 ± 0.001 * † |
|
|
|
|
Down-regulated by pioglitazone & palmitate vs. palmitate in diabetic human islets |
-7.1 ± 0.001 * † |
|
|
|
Pancreatic polypeptide (PPY) |
Up-regulated by exenatide & palmitate vs. palmitate in non-diabetic human islets |
4.1 ± 0.002 * † |
|
|
|
|
Up-regulated by pioglitazone & palmitate vs. palmitate in non-diabetic human islets |
4.7 ± 0.001 * † |
|
|
|
|
Up-regulated by palmitate vs. control in diabetic human islets |
6.6 ± 0.001 * † |
|
|
|
Regenerating islet-derived 3 alpha (REG3A) |
Up-regulated by exenatide & palmitate vs. palmitate in non-diabetic human islets |
2.1 ± 0.002* † |
|
Up-regulated by pioglitazone & palmitate vs. palmitate in non-diabetic human islets |
5.2 ± 0.001* † |
|
|
|
|
Down-regulated by pioglitazone & palmitate vs. palmitate in diabetic human islets |
-8.4 ± 0.001* † |
|
|
|
|
Up-regulated by palmitate vs. control in diabetic human islets |
10.3 ± 0.002* † |
|
|
|
Thioredoxin interacting protein (TXNIP) |
Up-regulated by exenatide & palmitate vs. palmitate in non-diabetic human islets |
12.6 ± 0.002 * † |
|
|
|
|
Up-regulated by pioglitazone & palmitate vs. palmitate in non-diabetic human islets |
16.0 ± 0.002* † |
|
|
|
|
Down-regulated by pioglitazone & palmitate vs. palmitate in diabetic human islets |
-16.6 ± 0.002* † |
|
|
|
Carboxyl ester lipase (CEL) |
Up-regulated by pioglitazone & palmitate vs. palmitate in diabetic human islets |
6.7 ± 0.001 * † |
|
|
|
|
Up-regulated by exenatide & palmitate vs. palmitate in diabetic human islets |
7.2 ± 0.001 *† |
|
|
|
Aryl hydrocarbon receptor nuclear translocator (ARNT) |
Down -regulated by exenatide & palmitate vs. palmitate in non-diabetic human islets |
-14.9 ± 0.001 * † |
|
|
|
|
Up-regulated by pioglitazone & palmitate vs. palmitate in diabetic human islets |
14.7 ± 0.001 * † |
|
|
|
|
Up-regulated by exenatide & palmitate vs. palmitate in diabetic human islets |
3.2 ± 0.002 *† |
|
|
|
ISL1 transcription factor, LIM/homeodomain (ISL1) |
Down-regulated by exenatide & palmitate vs. palmitate in diabetic human islets |
-3.1 ± 0.001 *† |
|
|
|
|
Up-regulated by palmitate vs. control in diabetic human islets |
2.3 ± 0.001* † |
|
|
|
Transcription factor 4 (TCF4/TCF7L2) |
Down-regulated by pioglitazone & palmitate vs. palmitate in diabetic human islets |
-1.9 ± 0.002 * † |
|
|
|
|
Down-regulated by exenatide & palmitate vs. palmitate in diabetic human islets |
-2.0 ± 0.002 *† |
|
|
|
|
Up-regulated by palmitate vs. control in diabetic human islets |
5.1 ± 0.002* † |
|
|
|
Defender against cell death 1 (DAD1) |
Up-regulated by exenatide & palmitate vs. palmitate in non-diabetic human islets |
7.9 ± 0.002 * † |
|
|
|
|
Up-regulated by pioglitazone & palmitate vs. palmitate in non-diabetic human islets |
4.1 ± 0.002 * † |
|
|
|
|
Up-regulated by palmitate vs. control in diabetic human islets |
2.1 ± 0.001* † |
